Description

• General description: Along with mitragynine, 7-Hydroxymitragynine is an active alkaloid found in the plant Mitragynine speciosa, commonly known as Kratom. The compound possesses opioid agonistic activity with a potentcy 30- and 17-fold higher than that of mitragynine and morphine, respectively.
• Application: 7-Hydroxymitragynine research solution for opioid receptor studies: The solution is utilized extensively in opioid receptor agonist research, providing insights into its binding efficacy and downstream effects in neurochemical pathways. This research contributes to understanding opioid-like effects and potential therapeutic uses for pain management and addiction treatment (Zhang et al., 2022).Kratom alkaloid standard in bioactive studies: As a bioactive mitragynine derivative, 7-Hydroxymitragynine is employed as a standard in the study of various kratom alkaloids, which aids in elucidating their pharmacological profiles and potential medicinal benefits. This is crucial for developing safe and effective kratom-based treatments (Henningfield et al., 2021).Analgesic compound research in pain management: Research on 7-Hydroxymitragynine focuses on its analgesic properties, exploring its effectiveness and safety as a pain-relieving compound. This research is vital for proposing alternatives to traditional opioids, offering potential benefits in terms of reduced side effects and lower addiction risks (Chakraborty et al., 2021).High-purity standard for synthetic studies: The high-purity 7-Hydroxymitragynine solution is critical for synthetic and biochemical assays, allowing researchers to study its effects on a molecular level in vitro. This facilitates a deeper understanding of its interaction with biological systems, aiding in the design of targeted pharmacotherapies (Bhowmik et al., 2021).Research-grade compound in neurochemistry: Used in neurochemistry to study the effects of kratom extracts and their derivatives, 7-Hydroxymitragynine solution helps delineate its role in altering neurotransmitter release. This research supports the development of novel therapies for disorders characterized by neurotransmitter dysregulation (Zhang et al., 2020).
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany